A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Regulation

EU Commission denies report on Astrazeneca lawsuit

Swedish-British pharmaceutical company Astrazeneca has not provided the agreed-upon vaccine doses, but the EU has not yet decided on legal recourse.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
BY RITZAU, TRANSLATED BY NIELSINE NIELSEN

In the last 24 hours, many media outlets have reported that the EU plans to file a lawsuit against the Swedish-British pharmaceutical company Astrazeneca for failing to provide the number of Covid-19 vaccine doses that are stated in its contract with the EU.

On Thursday, Ireland's Minister for Health Stephen Donnelly said that a legal case 'had been initiated', according to news media Reuters.

However, the EU Commission denies this statement, saying: "No decision to launch legal actions has been taken at this point in time".

In the Irish Parliament, Donnelly stated Ireland had joined the legal case alongside other EU countries.

The possible legal recourse revolves around the fact that Astrazeneca has failed to provide the doses that were agreed on in the contract for April, May and June, according to the minister.

The lawsuit would be played out in the Belgian court, since the parties agreed in the contract that any disputes will be handled there.

International media Politico reports that the question of possible legal recourse for Astrazeneca was raised by some EU countries' ambassadors to Brussels on Wednesday, when a majority of them supported the decision to file a suit, according to sources.

One diplomat said that the aim of the suit is to force Astrazeneca to deliver the vaccines that it promised the EU in the contract it signed. Astrazeneca has had huge supply chain problems and has been forced to warn of delays on several occasions.

The EU had intended that this vaccine would be the backbone of the first EU vaccine rollout, but in Q1, the vaccine producer could not deliver anywhere near the agreed-on amount of doses.

A failure to meet predicted supply has turned into something of a pattern for the company; the original contract stated that Astrazeneca would supply 180 million doses each quarter – but this has now been downgraded to around one third of that amount.

One high-ranking source was quoted on Wednesday as saying that the EU will not be utilizing the option of buying more doses of Astrazeneca's vaccine.

The vaccine, which is marketed under the name of Vaxzevria, has encountered problems with significant side effects and has been linked to a small number of cases of blood clots and low platelet counts among those who have received it. In several cases, this has led to death.

The vaccine has been removed from the vaccination plan in Denmark and Norway, and a number of other countries have introduced limitations on who may receive the vaccine – in many places, it is only being given to the elderly.

In Sweden, national epidemiologist Anders Tegnell has had his first dose of the Astrazeneca vaccine.

"I want to send an important signal that Astrazeneca is a fantastic vaccine for those aged 65 or over," he says to Swedish paper Corren. 

 

EU prepares to file lawsuit against Astrazeneca 

Share article

Related articles:

  • Empty vials of vaccines by Pfizer-BioNTech and AstraZeneca against Covid-19 caused by the novel coronavirus are pictured at the vaccination center in Rosenheim, southern Germany, on April 20, 2021, amid the novel coronavirus / COVID-19 pandemic | Photo: CHRISTOF STACHE/AFP / AFP

    EU prepares to file lawsuit against Astrazeneca

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers



Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Foto: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Foto: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


  • Foto: Tom Little

    Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

    The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

    For subscribers


  • Foto: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Foto: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


Further reading

Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers


Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.


Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Photo: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers


Jobs

  • Scientist - Bioanalysis, Biologics

  • Qualified Person to AJ Vaccines

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

  • VP of Software Development, Perfusion Tech

  • Global Medical Manager

  • Chemist for Incoming Materials in QC department

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Clinical Trial Manager

  • QA/RA Manager

  • Discovery Project Leader, Principal Scientist

  • Audit & Supplier Manager

  • Senior Legal Councel

  • Project Director, HR & ESG

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Scientist - Bioanalysis, Biologics

  • Qualified Person to AJ Vaccines

  • Senior QA Specialists (GMP or GCP)

  • Director, Head of Antibody Technology

  • VP of Software Development, Perfusion Tech

  • Global Medical Manager

  • Chemist for Incoming Materials in QC department

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Clinical Trial Manager

  • QA/RA Manager

  • Discovery Project Leader, Principal Scientist

  • Audit & Supplier Manager

  • Senior Legal Councel

  • Project Director, HR & ESG

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved